BackACRO Biomedical , Ltd. Overview

ACRO Biomedical , Ltd. Receivables

Track ACRO Biomedical , Ltd.'s receivables ($14M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$14.38M
↑ 271.45% YoYΔ $10.51M vs prior year quarter

Peer trimmed avg / median

Loading

ACRO Biomedical , Ltd. Receivables History

Loading

ACRO Biomedical , Ltd. vs. peers: Receivables Comparison

Loading

ACRO Biomedical , Ltd. Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

ACRO Biomedical , Ltd. (6748.TWO) FAQ

As of the most recent data (June 2026), 6748.TWO shows a receivables of $14M. That compares with $3.9M in the prior-year period — up 271.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 6748.TWO's receivables is now $14M (was $3.9M) — a 271.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether ACRO Biomedical , Ltd. is outperforming or lagging.

Tracking 6748.TWO's receivables over time shows whether ACRO Biomedical , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $14M That compares with $3.9M in the prior-year period — up 271.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has ACRO Biomedical , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $14M) with ownership activity and broader fundamentals.